Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum.

Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum

Authors: Nash, G.F., Turner, K.J., Hickish, T., Smith, J., Chand, M., Moran, B.J.

Journal: Annals of the Royal College of Surgeons of England

Publication Date: 01/10/2012

Volume: 94

Issue: 7

Pages: 456-462

ISSN: 0035-8843

DOI: 10.1308/003588412X13373405384611

Abstract:

Adenocarcinoma of the prostate and rectum are common male pelvic cancers and may present synchronously or metachronously due to their anatomic proximity. The treatment of rectal or prostate cancer (in particular surgery and/or radiotherapy) may alter the presentation, incidence and management should a metachronous tumour develop. This review focuses on the interaction between prostatic and rectal cancer diagnosis and management. We have restricted the scope of this large topic to general considerations, management of rectal cancer after prostate cancer treatment and vice versa, management of synchronous disease and cancer follow-up issues.

Source: Scopus

Authors: Nash, G.F., Turner, K.J., Hickish, T., Smith, J., Chand, M., Moran, B.J.

Journal: Ann R Coll Surg Engl

Publication Date: 10/2012

Volume: 94

Issue: 7

Pages: 456-462

eISSN: 1478-7083

DOI: 10.1308/003588412X13373405384611

Abstract:

Adenocarcinoma of the prostate and rectum are common male pelvic cancers and may present synchronously or metachronously due to their anatomic proximity. The treatment of rectal or prostate cancer (in particular surgery and/or radiotherapy) may alter the presentation, incidence and management should a metachronous tumour develop. This review focuses on the interaction between prostatic and rectal cancer diagnosis and management. We have restricted the scope of this large topic to general considerations, management of rectal cancer after prostate cancer treatment and vice versa, management of synchronous disease and cancer follow-up issues.

Source: PubMed

Preferred by: Guy Nash and Tamas Hickish